Anakinra treatment in patients with gout and type 2 diabetes

Clin Rheumatol. 2015 May;34(5):981-4. doi: 10.1007/s10067-014-2601-7. Epub 2014 Apr 15.

Abstract

We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone. The remarkable clinical improvement in joint symptoms within 24 h and in glycemic control during a 6-month period gives anakinra a potential therapeutic role in the management of gout and type 2 diabetes. When anakinra was discontinued, a gout attack occurred within 3-25 days in all three patients. The contribution of anakinra in the treatment of such syndromes is encouraging, but requires further studies to establish its long-term efficacy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Allopurinol / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Blood Glucose / metabolism
  • Carbamates / therapeutic use
  • Colchicine / therapeutic use
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Febuxostat / therapeutic use
  • Glycated Hemoglobin / metabolism
  • Gout / complications
  • Gout / drug therapy*
  • Gout Suppressants / therapeutic use*
  • Humans
  • Hyperuricemia / blood
  • Hyperuricemia / complications
  • Hyperuricemia / drug therapy*
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / therapeutic use
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Metformin / therapeutic use
  • Middle Aged
  • Piperidines / therapeutic use
  • Treatment Outcome
  • Uric Acid / blood

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antirheumatic Agents
  • Blood Glucose
  • Carbamates
  • Glycated Hemoglobin A
  • Gout Suppressants
  • Hypoglycemic Agents
  • Insulin
  • Interleukin 1 Receptor Antagonist Protein
  • Piperidines
  • hemoglobin A1c protein, human
  • Febuxostat
  • Uric Acid
  • Allopurinol
  • repaglinide
  • Metformin
  • Colchicine